News Related to Intracranial Hemorrhage

Related coverage linked through entity extraction aliases.

Phase 3 OCEANIC-STROKE trial shows asundexian cut recurrent ischemic stroke

Apr 20, 2026

Phase 3 OCEANIC-STROKE data showed asundexian plus antiplatelet therapy reduced recurrent ischemic stroke versus placebo. Major bleeding rates were similar between groups.

Cogent Biosciences Prepares Up to Three FDA Filings for Bezuclastinib Following Pivotal Wins

Mar 15, 2026

Cogent Biosciences is preparing parallel FDA submissions for bezuclastinib across three indications following positive pivotal trial results, with potential launches beginning in late 2026 and full commercialization expected by early 2027.